<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03894956</url>
  </required_header>
  <id_info>
    <org_study_id>P18-835</org_study_id>
    <nct_id>NCT03894956</nct_id>
  </id_info>
  <brief_title>Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa</brief_title>
  <official_title>Special Drug Use-Results Survey of Evaluating Safety and Effectiveness of Humira in Long Term Treatment in Patients With Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the long-term safety and effectiveness of Humira
      in patients with Hidradenitis Suppurativa (HS) in real-world clinical practice in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who reported any serious infections during the study</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Percentage of participants with incidence of serious infections are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who reported any adverse drug reactions (ADRs) during the study</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>ADRs will be coded by Medical Dictionary for Regulatory Activities (MedDRA) dictionary.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who reported any infections during the study</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Percentage of participants with incidence of infections are reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving &quot;Improved&quot; of overall improvement by physician</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Percentage of participants achieving overall improvement (improved, unchanged, impossible to evaluate) is assessed by physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR)</measure>
    <time_frame>Up to week 52</time_frame>
    <description>HiSCR is defined as at least 50% reduction in the number of abscesses and inflammatory nodules and no increase in abscess count and no increase in draining fistula count relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-Reactive Protein (CRP)</measure>
    <time_frame>From Baseline to Week 52</time_frame>
    <description>CRP values are measured as an inflammatory parameter. Low CRP values mean less inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient's global assessment of skin pain</measure>
    <time_frame>From Baseline to Week 52</time_frame>
    <description>Patient's global assessment of skin pain is evaluated on a 11-point scale with 0 for &quot;no pain&quot; and 10 for &quot;worst skin pain imaginable.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>From Baseline to Week 52</time_frame>
    <description>DLQI is a 10-question validated dermatologic disease questionnaire to measure quality of life.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hidradenitis Suppurativa (HS)</condition>
  <arm_group>
    <arm_group_label>Participants with Hidradenitis Suppurativa (HS)</arm_group_label>
    <description>Participants who along with their treating physician have elected for treatment with Humira as per routine clinical practice for the treatment of HS</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hidradenitis Suppurativa (HS)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who have been prescribed Humira by their treating physician as per
             routine clinical practice for the treatment of HS.

        Exclusion Criteria:

          -  Participants previously treated with Humira.

          -  Participants who do not provide consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie GK Clinical Trial Registration Desk</last_name>
    <phone>+81-3-4577-1111</phone>
    <email>abbvie_jpn_info_clingov@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ehime University Hospital /ID# 214090</name>
      <address>
        <city>Toon</city>
        <zip>791-0204</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hidradenitis Suppurativa (HS)</keyword>
  <keyword>Humira</keyword>
  <keyword>Adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

